Comparing the current results to its competitors, Enact Holdings Inc reported Revenue increase in the 1 quarter 2026 by 1.73 % year on year. The revenue growth was below Enact Holdings Inc 's competitors' average revenue growth of 20.6 %, achieved in the same quarter.
Enact Holdings Inc Net Income in the 1 quarter 2026 grew year on year by 1.2%, while most of its competitors have experienced a contraction in net income by -35.44 %.
Enact Holdings Inc 's Comment on Competition and Industry Peers
Enact focuses on underwriting to a well-established, diverse customer base. The company plans to invest in differentiation, efficiency, and decision-making improvements. It maintains strong capital levels and earnings through underwriting standards, stress testing, a conservative leverage ratio, and a diversified CRT program. Enact also aims to optimize cost of capital and capacity across CRT channels to manage volatility, protect the balance sheet, and enhance return on equity.
April 3, 2024
Continuing its streak as a frontrunner in the financial industry, Enact Holdings, Inc. (Nasdaq: ACT) (Enact) announced its seamless integration with PMI Rate Pro. Based in Raleigh, North Carolina, Enact, known for providing top-tier private mortgage insurance through its insurance subsidiaries, announced this collaboration on April 3, 2024. This feat would enhance the company s operations by facilitating direct orders for delegated mortgage insurance through PMI Rate Pro s API platform.Enact s integration with PMI Rate Pro promises a tangible boost in productivity for lenders. It underlines the company s commitment to harness the potential of innovative digital resources to optimize its operations. The fact ...
February 1, 2024
Enact Holdings Inc Secures $255 Million in Reinsurance Coverage Amid Revenue GrowthEnact Holdings Inc, a leading credit risk transfer program provider, recently completed a Forward XOL Reinsurance Transaction, securing approximately $255 million of excess of loss reinsurance coverage from a panel of reinsurers. This strategic move is a part of Enact s diversified credit risk transfer program and showcases the company s commitment to managing risk effectively. In the 3rd quarter of 2023, Enact reported an impressive 8.71% increase in revenue compared to the previous year. This growth stands out among its competitors, as most of them experienced a significant contraction in revenues, at a rate of -8.5%, during...
Enact Holdings Inc, a prominent player in the mortgage insurance industry, has recently completed its sixth Mortgage Insurance Linked Note Credit Risk Transaction, marking a significant milestone in its Diversified Credit Risk Transfer Program. Through its Triangle Re Insurance Linked Note platform, the company has secured an impressive $248 million of fully collateralized excess of loss insurance coverage. As Enact fortifies its risk mitigation strategy, it is noteworthy to compare its financial performance to its competitors. Revenue Growth Analysis: In the third quarter of 2023, Enact Holdings Inc has reported an impressive 8.71% year-on-year increase in revenue. This growth reflects the...
Pfizer Inc operates as a global pharmaceutical company that focuses on researching, developing, manufacturing, and marketing innovative medicines. Its business model emphasizes significant investment in research and development to build a diverse portfolio of therapies across various therapeutic areas, while leveraging strategic alliances and collaborations to enhance commercialization and drive growth.
Merck & Co. Inc. operates primarily as a research-driven pharmaceutical company, focused on the development, manufacturing, and marketing of prescription drugs and vaccines globally. It aims to address unmet medical needs through innovative research, collaborations, and rigorous clinical trials, while promoting patient well-being and contributing to global healthcare with high-quality, affordable medications.
Eli Lilly and Company operates as a global pharmaceutical firm that focuses on developing innovative medicines in areas such as diabetes, oncology, and neurodegeneration. Their business model emphasizes research and development, strategic partnerships, and a strong commitment to improving patient outcomes through advanced therapeutics.
Johnson & Johnson operates as a multinational healthcare company with a diversified business model that spans pharmaceuticals, medical devices, and consumer health products. By focusing on innovation and strategic acquisitions, the company aims to improve global health and well-being.
Bristol Myers Squibb Company operates a research and development-driven business model, focusing on the discovery and delivery of innovative medicines for various diseases. It emphasizes collaboration with academic institutions, government entities, and other pharmaceutical firms to enhance its therapeutic portfolio and improve patient outcomes.
Sources:
Enact Holdings Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Enact Holdings Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
